Advertisement

Pancreatic Cancer pp 1125-1139 | Cite as

Management of Cystic Neoplasms of the Pancreas

  • Cristina R. Ferrone
  • Carlos Fernandez-del Castillo
  • Andrew L. Warshaw
Reference work entry

Abstract:

The classification and management of cystic neoplasms of the pancreas has changed dramatically over the past 30 years. The pathologic differential diagnosis of this heterogeneous group of lesions began in 1978 with landmark publications by Compagno and Oertel [1,2]. Serous cystic lesions, mucinous cystic lesions and intraductal papillary mucinous neoplasms (IPMNs) together comprise about 90% of cystic neoplasms of the pancreas. Serous cystadenomas are indolent slow-growing tumors which are firm, well-circumscribed, and multinodular. Mucinous cystic neoplasms (MCNs) have an ovarian-like stromal layer and encompass a wide spectrum from benign lesions with malignant potential to aggressive carcinomas. These lesions demonstrate histologic heterogeneity, with benign-appearing and malignant epithelia in almost every lesion. One of the most common lesions identified in the pancreas is the IPMN. Of the two variants the main duct IPMNs are more aggressive than the branch duct IPMNs. Currently, incidentally discovered cysts comprise up to 71% of cystic lesions identified. The management of cystic lesions has evolved from resection of all lesions, to selective resection or close follow-up with imaging, due to the improved understanding of the natural history of these lesions. This chapter will address the surgical management of serous cystic lesions, mucinous cystic lesions and IPMNs.

Keywords

Cystic Lesion Main Pancreatic Duct Cystic Neoplasm Intraductal Papillary Mucinous Neoplasm Massachusetts General Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Compagno J, Oertel JE: Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am J Clin Pathol 1978;69:573–580.PubMedGoogle Scholar
  2. 2.
    Compagno J, Oertel JE: Microcystic adenomas of the pancreas (glycogen-rich cystadenomas): a clinicopathologic study of 34 cases. Am J Clin Pathol 1978;69:289–298.PubMedGoogle Scholar
  3. 3.
    Balcom JH, Rattner DW, Warshaw AL, et al.: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001;136:391–398.CrossRefPubMedGoogle Scholar
  4. 4.
    Bentrem DJ, Yeh JJ, Brennan MF, et al.: Predictors of intensive care unit admission and related outcome for patients after pancreaticoduodenectomy. J Gastrointest Surg 2005;9:1307–1312.CrossRefPubMedGoogle Scholar
  5. 5.
    Bentrem DJ, Brennan MF: Outcomes in oncologic surgery: does volume make a difference? World J Surg 2005;29:1210–1216.CrossRefPubMedGoogle Scholar
  6. 6.
    Ferrone CR, Kattan MW, Tomlinson JS, et al.: Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 2005;23:7529–7535.CrossRefPubMedGoogle Scholar
  7. 7.
    Tseng JF, Warshaw AL, Sahani DV, et al.: Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg 2005;242:413–419; discussion 419–21.PubMedGoogle Scholar
  8. 8.
    Bassi C, Salvia R, Molinari E, et al.: Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms and see at imaging or vice versa? World J Surg 2003;27:319–323.CrossRefPubMedGoogle Scholar
  9. 9.
    Strobel O, Z’Graggen K, Schmitz-Winnenthal FH, et al.: Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion 2003;68:24–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Abe H, Kubota K, Mori M, et al.: Serous cystadenoma of the pancreas with invasive growth: benign or malignant? Am J Gastroenterol 1998;93:1963–1966.CrossRefPubMedGoogle Scholar
  11. 11.
    Pyke CM, van Heerden JA, Colby TV, et al.: The spectrum of serous cystadenoma of the pancreas. Clinical, pathologic, and surgical aspects. Ann Surg 1992;215:132–139.CrossRefPubMedGoogle Scholar
  12. 12.
    Fernandez-del Castillo C, Targarona J, Thayer SP, et al.: Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138:427–434; discussion 433–434.CrossRefPubMedGoogle Scholar
  13. 13.
    Hammel PR, Vilgrain V, Terris B, et al.: Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087–1095.CrossRefPubMedGoogle Scholar
  14. 14.
    Warshaw AL: Conservation of the spleen with distal pancreatectomy. Arch Surg 1988;123:550–553.PubMedGoogle Scholar
  15. 15.
    Tanaka M, Chari S, Adsay V, et al.: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Wilentz RE, Albores-Saavedra J, Zahurak M, et al.: Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 1999;23:1320–1327.CrossRefPubMedGoogle Scholar
  17. 17.
    Zamboni G, Scarpa A, Bogina G, et al.: Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999;23:410–422.CrossRefPubMedGoogle Scholar
  18. 18.
    Le Borgne J, de Calan L, Partensky C: Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 1999;230:152–161.CrossRefPubMedGoogle Scholar
  19. 19.
    Sarr MG, Carpenter HA, Prabhakar LP, et al.: Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg 2000;231:205–212.CrossRefPubMedGoogle Scholar
  20. 20.
    Crippa S, Salvia R, Warshaw AL, et al.: Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 2008;247:571–579.CrossRefPubMedGoogle Scholar
  21. 21.
    Thompson LD, Becker RC, Przygodzki RM, et al.: Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg Pathol 1999;23:1–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Jimenez RE, Warshaw AL, Z’Graggen K, et al.: Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 1999;230:501–509; discussion 509–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Ferrone CR, Brennan MF, Gonen M, et al.: Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008;12:701–706.CrossRefPubMedGoogle Scholar
  24. 24.
    Ohashi k, Murakami Y, Maruyamacm.: Four cases of mucin producing cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endoscopy 1982;20:348–351.Google Scholar
  25. 25.
    Schnelldorfer T, Sarr MG, Nagorney DM, et al.: Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg 2008;143:639–646; discussion 646.CrossRefPubMedGoogle Scholar
  26. 26.
    Wada K, Takada T, Yasuda H, et al.: Does “clonal progression” relate to the development of intraductal papillary mucinous tumors of the pancreas? J Gastrointest Surg 2004;8:289–296.CrossRefPubMedGoogle Scholar
  27. 27.
    Terris B, Ponsot P, Paye F, et al.: Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372–1377.CrossRefPubMedGoogle Scholar
  28. 28.
    Kobari M, Egawa S, Shibuya K, et al.: Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999;134:1131–1136.CrossRefPubMedGoogle Scholar
  29. 29.
    Doi R, Fujimoto K, Wada M, et al.: Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002;132:80–85.CrossRefPubMedGoogle Scholar
  30. 30.
    Matsumoto T, Aramaki M, Yada K, et al.: Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 2003;36:261–265.CrossRefPubMedGoogle Scholar
  31. 31.
    Choi BS, Kim TK, Kim AY, et al.: Differential diagnosis of benign and malignant intraductal papillary mucinous tumors of the pancreas: MR cholangiopancreatography and MR angiography. Korean J Radiol 2003;4:157–162.CrossRefPubMedGoogle Scholar
  32. 32.
    Kitagawa Y, Unger TA, Taylor S, et al.: Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg 2003;7:12–18; discussion 18–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Sugiyama M, Izumisato Y, Abe N, et al.: Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003;90:1244–1249.CrossRefPubMedGoogle Scholar
  34. 34.
    Sohn TA, Yeo CJ, Cameron JL, et al.: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788–797; discussion 797–799.CrossRefPubMedGoogle Scholar
  35. 35.
    Salvia R, Fernandez-del Castillo C, Bassi C, et al.: Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004;239:678–685; discussion 685–687.CrossRefPubMedGoogle Scholar
  36. 36.
    Ogawa H, Itoh S, Ikeda M, et al.: Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology 2008;248:876–886.CrossRefPubMedGoogle Scholar
  37. 37.
    Thayer SP, Fernandez-del Castillo C, Balcom JH, et al.: Complete dorsal pancreatectomy with preservation of the ventral pancreas: a new surgical technique. Surgery 2002;131:577–580.CrossRefPubMedGoogle Scholar
  38. 38.
    Falconi M, Salvia R, Bassi C, et al.: Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg 2001;88:376–381.CrossRefPubMedGoogle Scholar
  39. 39.
    Bassi C, Sarr MG, Lillemoe KD, et al.: Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg 2008;12:645–650.CrossRefPubMedGoogle Scholar
  40. 40.
    Chari ST, Yadav D, Smyrk TC, et al.: Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500–1507.CrossRefPubMedGoogle Scholar
  41. 41.
    Sho M, Nakajima Y, Kanehiro H, et al.: Pattern of recurrence after resection for intraductal papillary mucinous tumors of the pancreas. World J Surg 1998;22:874–878.CrossRefPubMedGoogle Scholar
  42. 42.
    Irie H, Yoshimitsu K, Aibe H, et al.: Natural history of pancreatic intraductal papillary mucinous tumor of branch duct type: follow-up study by magnetic resonance cholangiopancreatography. J Comput Assist Tomogr 2004;28:117–122.CrossRefPubMedGoogle Scholar
  43. 43.
    Bernard P, Scoazec JY, Joubert M, et al.: Intraductal papillary-mucinous tumors of the pancreas: predictive criteria of malignancy according to pathological examination of 53 cases. Arch Surg 2002;137:1274–1278.CrossRefPubMedGoogle Scholar
  44. 44.
    Rodriguez JR, Salvia R, Crippa S, et al.: Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133:72–79; quiz 309–310.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Cristina R. Ferrone
    • 1
  • Carlos Fernandez-del Castillo
    • 1
  • Andrew L. Warshaw
    • 1
  1. 1.Massachusetts General HospitalBostonUSA

Personalised recommendations